



For immediate release – January 24, 2008

## REVENUE GROWS BY 10.3% IN 2007, TO €233.4 M

Consolidated revenue, in €M	2007	2006	Change
1st quarter	53.2	45.2	+17.6%
2 <sup>nd</sup> quarter	57.9	53.2	+8.8%
3rd quarter	54.9	50.8	+8.2%
4th quarter	67.4	62.4	+8.0%
<b>Total for the year</b>	<b>233.4</b>	<b>211.6</b>	<b>+10.3%</b>

January 24, 2008 – (Lure, France) – **Vétoquinol earned revenue of €233.4 million in 2007, compared with €211.6 million over the same period one year earlier.** On a constant exchange rate and scope of business basis, revenue growth for 2007 was 7.6%.

Business for the fourth quarter of the year just ended was sustained and in line with the group's forecasts. For 2007 as a whole, revenue growth exceeded 10%, attributable in particular to higher sales for the product portfolio, as well as to the introduction of new drugs and the full-year integration of Vet Solutions into Vétoquinol USA. Sales denominated in USD accounted for around 10% of consolidated revenue in 2007.

Sales growth was significant in all of the group's strategic geographic regions (Europe, North America and Asia) and for all species (companion animals as well as livestock), with a healthy balance maintained between species.

*"Growth in our business last year will boost our operating margin and net earnings, in line with our most recent guidance,"* noted Etienne Frechin, Chairman and CEO of Vétoquinol. *"We are ahead of target with respect to our business model, and are confident in our ability to achieve further earnings growth in 2008."*

Upcoming events: 2007 Annual results (Tuesday, 18 March 2008)

**About Vétoquinol**

*Vétoquinol, established in 1933, is an independent veterinary pharmaceutical laboratory for both food producing animals and pets. This family-owned Group, dedicated to animal health, is the world's 12<sup>th</sup> largest laboratory in its field. Nearly 80% of its revenue is now generated in export markets.*

*Its business includes research, production and marketing of drugs and health products. Vétoquinol, positioned in the treatment field, has extensive expertise in 3 major therapeutic fields: anti-infection agents, pain and inflammatory, and cardiology-nephrology.*

*The Group now distributes its products in about one hundred countries (Europe, North America and Asia), working through 18 subsidiaries and a network of 110 distributor-partners. The company had more than 1,300 employees worldwide.*

**More information:** [www.vetoquinol.com](http://www.vetoquinol.com).

**OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.**

For further information, contact

**VETOQUINOL**

Finance Department

Tel.: +33 (0)3 84 62 59 88

[relations.investisseurs@vetoquinol.com](mailto:relations.investisseurs@vetoquinol.com)

**KEIMA COMMUNICATION**

Investor Relations

Emmanuel DOVERGNE

Tel.: +33 (0)1 56 43 44 63

[emmanuel.dovergne@keima.fr](mailto:emmanuel.dovergne@keima.fr)

Media Relations

Alix HERIARD DUBREUIL

Tel.: +33 (0)1 56 43 44 62

[alix.heriard@keima.fr](mailto:alix.heriard@keima.fr)